KR920703040A - 진경 특성 및 신경보호특성을 갖는 아릴알킬-아민 및-아미드 - Google Patents

진경 특성 및 신경보호특성을 갖는 아릴알킬-아민 및-아미드

Info

Publication number
KR920703040A
KR920703040A KR1019920701879A KR920701879A KR920703040A KR 920703040 A KR920703040 A KR 920703040A KR 1019920701879 A KR1019920701879 A KR 1019920701879A KR 920701879 A KR920701879 A KR 920701879A KR 920703040 A KR920703040 A KR 920703040A
Authority
KR
South Korea
Prior art keywords
phenyl
amino
acetamide
methylethyl
propylamine
Prior art date
Application number
KR1019920701879A
Other languages
English (en)
Other versions
KR0169998B1 (ko
Inventor
제이. 네이피어 제임스
씨. 그리피쓰 로날드
Original Assignee
크리스토퍼 브래드베리 크레이그
피존스 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 크리스토퍼 브래드베리 크레이그, 피존스 코포레이션 filed Critical 크리스토퍼 브래드베리 크레이그
Publication of KR920703040A publication Critical patent/KR920703040A/ko
Application granted granted Critical
Publication of KR0169998B1 publication Critical patent/KR0169998B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/52—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/10—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pyridine Compounds (AREA)
  • Fats And Perfumes (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

내용 없음

Description

진경 특성 및 신경보호특성을 갖는 아릴알킬-아민 및-아미드
[도면의 간단한 설명]
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 약제학적으로 허용되는 보조제, 희석제 또는 담체와 함께 하기 일반식(I)의 화합물 또는 이의 약제학적으로 허용되는 염을 포함하는 약제학적 조성물.
    상기식에서, Ar1및 Ar2는 동일하거나 상이할 수 있으며, 하나이상의 아미노, 니트로, 염소, 브롬, 하이드록시, C1-C6알콕시, C1-C6알킬 또는 시아노에 의해 독립적으로 치환된 페닐이거나 Ar1또는 Ar2는 또한 페닐일 수 있고; R1은 수소 또는 C1-C6알킬이며, R2는 수소 또는 COCH2NH2이고; R3는 수소 또는 C1-C6알킬이며; 단, R2가 수소인 경우, Ar1및 Ar2중의 하나 또는 모두는 또한 페닐, 플루오로페닐 또는 2-, 3- 또는 4-피리디닐일 수 있고 R1은 또한 C1-C6알콕시카보닐 또는 트리플루오로메틸이다.
  2. 하기 일반식(IA)의 화합물 및 이의 약제학적으로 허용되는 염.
    상기식에서, Ar1a, R1a, R2a및 R3a는 제1항의 Ar1, Ar2, R1, R2및 R3에 대해 각각 정의된 바와 같으며, 단, R2a가 수소인 경우, R1a는 C1-C6알킬이다.
  3. 제2항에 있어서, Ar1a및 Ar2a중의 하나 또는 모두가 4-하이드록시페닐인 화합물.
  4. 제2항에 있어서, Ar1a및 Ar2a가 일- 또는 이치환된 화합물.
  5. 제2항에 있어서, R1a가 메틸인 화합물.
  6. 제2항에 있어서, R3a가 메틸인 화합물.
  7. 신경계 질환으로 고통을 받는 환자에게, 제1항에서 정의한 바와 같은 일반식(I)의 화합물 또는 이의 약제학적으로 허용되는 염을 투여함을 특징으로 하여, 신경계 질환을 치료하거나 예방하는 방법.
  8. 제2항에 있어서, 화합물이:1-(4-하이드록시페닐)-2-페닐-2-프로필아민; 1-(4-하이드록시페닐)-2-페닐에틸아민; 1-페닐-2-(4-하이드록시페닐)에틸아민; 1,2-비스(4-하이드록시페닐)에틸아민; 1-페닐-2-(4-하이드록시페닐)-2-프로필아민; 1,2-비스(4-하이드록시페닐)-2-프로필아민; 1-(3-니트로페닐)-2-페닐-2-프로필아민; 1-(3-클로로페닐)-2-페닐-2-프로필아민; 1-(3-브로모페닐)-2-페닐-2-프로필아민; 1-(3-시아노페닐)-2-페닐-2-프로필아민; 2-(2-메틸페닐)-1-페닐-2-프로필아민; 1-(4-클로로페닐)-2-페닐-2-프로필아민; 1-페닐-2-(3,4-디클로로페닐)-2-프로필아민; 1-페닐-2-(3-메톡시페닐)-2-프로필아민; 1-페닐-2-[3-((2,2,2-트리클로로에톡시카보닐)아미노)페닐]-2-프로필아민; 2-(3-클로로페닐)-1-페닐-2-프로필아민; 1-(2-클로로페닐)-2-페닐-2-프로필아민; 2-(2-클로로페닐)-1-페닐-2-프로필아민; 1-(3-니트로페닐)-1-페닐-2-프로필아민; 2-(4-클로로페닐)-1-페닐-2-프로필아민; 2-(3,4-디메톡시페닐)-1-페닐-2-프로필아민; 2-(4-메틸페닐)-1-페닐-2-프로필아민; 2-(4-메톡시페닐)-1-페닐-2-프로필아민; 1-(3,4-디클로로페닐)-2-페닐-2-프로필아민; 1-(4-메톡시페닐)-2-페닐-2-프로필아민; 2-아미노-N-[1-(3-클로로페닐)-2-페닐-1-메틸에틸]아세트아미드; 2-아미노-N-[2-(2-클로로페닐)-1-페닐-1-메틸에틸]아세트아미드; 2-아미노-N-[2-(4-클로로페닐)-1-페닐-1-메틸에틸]아세트아미드; 2-아미노-N-[1-(2-메틸페닐)-2-페닐-1-메틸에틸]아세트아미드; 2-아미노-N-[1-(2-클로로페닐)-2-페닐-1-메틸에틸]아세트아미드; 2-아미노-N-[2-(3-클로로페닐)-1-페닐-1-메틸에틸]아세트아미드; 2-아미노-N-[2-(3-아미노페닐)-1-페닐-1-메틸에틸]아세트아미드; 2-아미노-N-[2-(3-브로모페닐)-1-페닐-1-메틸에틸]아세트아미드; 2-아미노-N-[2-(3-니트로페닐)-1-페닐-1-메틸에틸]아세트아미드; 2-아미노-N-[1-(3-니트로페닐)-2-페닐-1-메틸에틸]아세트아미드; 2-아미노-N-[1-(3-아미노페닐)-2-페닐-1-메틸에틸]아세트아미드; 2-아미노-N-[1-(4- 클로로페닐)-2-페닐-1-메틸에틸]아세트아미드; 2-아미노-N-[1-(3,4-디클로로페닐)-2-페닐-1-메틸에틸]아세트아미드; 2-아미노-N-[1-(3,4-디메톡시페닐)-2-페닐-1-메틸에틸]아세트아미드; 2-아미노-N-[2-(3-시아노페닐)-1-페닐-1-메틸에틸]아세트아미드; 2-아미노-N-[1-(4-메틸페닐)-2-페닐-1-메틸에틸]아세트아미드; 2-아미노-N-[1-(4-하이드록시페닐)-2-페닐-1-메틸에틸]아세트아미드; 2-아미노-N-[1-(4-하이드록시페닐)-2-페닐에틸]아세트아미드; 2-아미노-N-[1-(4-하이드록시페닐)-1-페닐-1-메틸에틸]아세트아미드; 2-아미노-N-[2-(4-하이드록시페닐)-1-페닐에틸]아세트아미드; 2-아미노-N-[1,2-비스(4-하이드록시페닐)-1-메틸에틸]아세트아미드; 2-아미노-N-[1,2-비스(4-하이드록시페닐)에틸]아세트아미드; 2-아미노-N-[1-(3-메톡시페닐)-2-페닐-1-메틸에틸]아세트아미드; 2-아미노-N-[1-(4-메톡시페닐)-2-페닐-1-메틸에틸]아세트아미드; 2-아미노-N-[2-(3,4-디클로로페닐)-1-페닐-1-메틸에틸]아세트아미드; 2-아미노-N-[2-(4-메톡시페닐)-1-페닐-1-메틸에틸]아세트아미드; 또는 이의 약제학적으로 허용되는 염인 화합물.
    ※ 참고사항:최초출원 내용에 의하여 공개하는 것임.
KR1019920701879A 1988-08-12 1990-02-07 진경 특성 및 신경보호 특성을 갖는 아릴알킬아민 및 아릴알킬아미드 KR0169998B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23256688A 1988-08-12 1988-08-12
PCT/GB1990/000184 WO1991011995A1 (en) 1988-08-12 1990-02-07 Arylalkyl-amines and -amides having anticonvulsant and neuroprotective properties

Publications (2)

Publication Number Publication Date
KR920703040A true KR920703040A (ko) 1992-12-17
KR0169998B1 KR0169998B1 (ko) 1999-02-01

Family

ID=22873660

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920701879A KR0169998B1 (ko) 1988-08-12 1990-02-07 진경 특성 및 신경보호 특성을 갖는 아릴알킬아민 및 아릴알킬아미드

Country Status (19)

Country Link
EP (3) EP0356035B1 (ko)
JP (2) JP2846895B2 (ko)
KR (1) KR0169998B1 (ko)
AT (1) ATE135206T1 (ko)
AU (1) AU654802B2 (ko)
CA (1) CA1341136C (ko)
DE (1) DE68925933T2 (ko)
DK (2) DK175755B1 (ko)
ES (1) ES2083972T3 (ko)
FI (1) FI111712B (ko)
GR (1) GR3020407T3 (ko)
HU (1) HU211467A9 (ko)
IE (3) IE74216B1 (ko)
LV (1) LV11817B (ko)
NO (1) NO301974B1 (ko)
PT (1) PT91435B (ko)
SG (1) SG52662A1 (ko)
WO (1) WO1991011995A1 (ko)
ZA (1) ZA90878B (ko)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9320273D0 (en) * 1993-04-01 1993-11-17 Fisons Corp Compound useful in therapy
US5455259A (en) * 1987-02-06 1995-10-03 Fisons Corporation Compounds for the treatment of neurodegenerative disorders
ZA908490B (en) * 1989-10-27 1991-07-31 Fisons Corp Use of arylalkylamides in the treatment of neurodegenerative diseases
EP0572560B1 (en) * 1991-02-22 2003-01-29 SHAPIRO, Howard, K. Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology
EP0540318A1 (en) * 1991-10-30 1993-05-05 Fisons Corporation 2-Heterocyclicethylamine derivatives and their use as pharmaceuticals
SG47948A1 (en) * 1992-04-03 1998-04-17 Astra Ab Compounds for the treatment of neurodegenerative disorders
ZA942140B (en) * 1993-04-01 1994-10-03 Fisons Corp Salt of (S)-alpha-phenyl-2-pyridineethanamine useful in therapy
GB9410320D0 (en) * 1994-05-24 1994-07-13 Fisons Corp Novel therapeutic method
SE9901237D0 (sv) * 1999-04-06 1999-04-06 Astra Ab Novel use
PT1545613E (pt) 2002-07-31 2011-09-27 Seattle Genetics Inc Conjugados de auristatina e sua utilização para tratamento do cancro, de uma doença autoimune ou de uma doença infecciosa
WO2007017652A2 (en) * 2005-08-10 2007-02-15 Astrazeneca Ab Arylakylamines for the treatment of cancer
MX2011006680A (es) 2008-12-24 2011-07-12 Astrazeneca Ab Compuestos etanaminicos y su uso para tratar la depresion.
TR201909632T4 (tr) * 2013-11-05 2019-07-22 Astrazeneca Ab Nmda antagonisti ön ilaçları.

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2503285A (en) * 1945-10-18 1950-04-11 Winthrop Stearns Inc Beta-substituted alpha, beta-diphenylethylamines and the preparation thereof
US2691680A (en) * 1951-06-16 1954-10-12 George A Breon And Company N-methyl-1-(3-hydroxyphenyl)-2-phenylethylamine and addition salts thereof
CH343388A (de) * 1956-03-09 1959-12-31 Cilag Chemie Aktiengesellschaf Verfahren zur Herstellung neuer Amide
NL128079C (ko) * 1958-04-02
NL6512616A (ko) * 1964-09-30 1966-03-31
ES484553A1 (es) * 1978-10-05 1980-05-16 Hoechst Ag Un metodo para preparar 4-fenil-1,3-benzodiazepinas
US4757076A (en) * 1984-06-18 1988-07-12 Eli Lilly And Company Method of inhibiting aromatase
HU207280B (en) * 1986-09-25 1993-03-29 Chinoin Gyogyszer Es Vegyeszet Process for producing new phenyl-alkyl-amines and pharmaceutical compositions containing them
IL84305A (en) * 1987-02-06 1992-01-15 Fisons Corp 2-aminoacetamide derivatives
US4798687A (en) * 1987-02-06 1989-01-17 Pennwalt Corporation 2-Amino-N-[1,2-Diphenyl-1-(thifluoromethyl)ethyl]acetamide derivatives
GB9320273D0 (en) * 1993-04-01 1993-11-17 Fisons Corp Compound useful in therapy
US4769466A (en) * 1987-02-06 1988-09-06 Pennwalt Corporation 2-aminoacetamide pyridinyl derivatives
EP0322582A3 (en) * 1987-12-07 1989-09-13 Hoechst-Roussel Pharmaceuticals Incorporated 4-heteroaryl-1,3-benzodiazepines and 2-substituted-alpha-(heteroaryl)benzeneethanamines, a process for their preparation and their use us medicaments
EP0401253A1 (en) * 1988-01-20 1990-12-12 Fisons Corporation 2-amino acetamide derivatives
GB8801883D0 (en) * 1988-01-28 1988-02-24 Oldham Crompton Batteries Ltd Improvements in/relating to clamp reflectors
ZA908490B (en) * 1989-10-27 1991-07-31 Fisons Corp Use of arylalkylamides in the treatment of neurodegenerative diseases
SG47948A1 (en) * 1992-04-03 1998-04-17 Astra Ab Compounds for the treatment of neurodegenerative disorders

Also Published As

Publication number Publication date
ES2083972T3 (es) 1996-05-01
IE74216B1 (en) 1997-07-16
GR3020407T3 (en) 1996-09-30
JPH02131452A (ja) 1990-05-21
DK394189D0 (da) 1989-08-11
DK394189A (da) 1990-02-13
ATE135206T1 (de) 1996-03-15
DK175755B1 (da) 2005-02-07
LV11817B (en) 1997-12-20
JPH08291112A (ja) 1996-11-05
PT91435A (pt) 1990-03-08
FI923540A0 (fi) 1992-08-06
NO923006D0 (no) 1992-07-30
HU211467A9 (en) 1995-11-28
FI111712B (fi) 2003-09-15
DK78995A (da) 1995-07-05
EP0356035A3 (en) 1991-04-03
IE892596L (en) 1990-02-12
IE960774L (en) 1990-02-12
JP2846895B2 (ja) 1999-01-13
EP0648745A1 (en) 1995-04-19
EP0356035A2 (en) 1990-02-28
WO1991011995A1 (en) 1991-08-22
NO923006L (no) 1992-07-30
SG52662A1 (en) 1998-09-28
DE68925933D1 (de) 1996-04-18
IE960775L (en) 1990-02-12
NO301974B1 (no) 1998-01-05
AU5092790A (en) 1991-09-03
CA1341136C (en) 2000-11-07
KR0169998B1 (ko) 1999-02-01
ZA90878B (en) 1990-11-28
EP0356035B1 (en) 1996-03-13
AU654802B2 (en) 1994-11-24
LV11817A (lv) 1997-08-20
DE68925933T2 (de) 1996-08-14
EP0648489A1 (en) 1995-04-19
PT91435B (pt) 1994-07-29
FI923540A (fi) 1992-08-06

Similar Documents

Publication Publication Date Title
KR920703040A (ko) 진경 특성 및 신경보호특성을 갖는 아릴알킬-아민 및-아미드
RU2006101458A (ru) 2-аминобензотиазолы в качестве обратных агонистов рецепторов cb1
HUP0202623A2 (hu) MEK-gátló vegyületek alkalmazása gyógyászati készítmények előállítására
JP2008516986A5 (ko)
NO914528L (no) N-substituerte heterocykliske derivater, deres fremstilling og farmasoeytiske preparater som inneholder dem
ATE450532T1 (de) Pyridinyl- oder pyrimidinylthiazole mit proteinkinasehemmender wirkung
CA2583217A1 (en) 1,3,4-thiadiazole compounds as protein kinase inhibitors
BR0214989A (pt) Composto, formulação farmacêutica, uso de um composto, método de tratamento de doenças, e, processo para a preparação de um composto
RU97111792A (ru) Производные анилина, обладающие ингибирующим действием на синтазу окисла азота
KR950701223A (ko) 항허혈성(Anti-ichemic)약물
EA200501703A1 (ru) Применение производных азетидинкарбоксамида в терапии
ATE361918T1 (de) 4-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2- yl)harnstoff und dessen verwendung bei der behandlung von mit glycogensynthasekinase-3 (gsk3) assoziierten leiden
RU98119076A (ru) Производные 2-(3h)-оксазолона и их применение в качестве ингибиторов сох-2
HUP0300298A2 (hu) 4-[Piperazinil-8-(kinolinil-metil)]benzamid-származékok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
RU94045271A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования синдрома тернера
AR047975A1 (es) Bloqueadores de kv1.5 para aumentar selectivamente la contractilidad auricular y tratar la insuficiencia cardiaca
KR900018042A (ko) 부텐산 유도체
KR940005475A (ko) 3- 아미노에틸 인돌로부터 유도되는 아미딘 및 이의 제조방법
RU2347783C2 (ru) Производные диазепана, их применение в качестве ингибиторов lfa, способ лечения заболеваний, опосредованных взаимодействием с lfa-1/icam-1
DE60208347D1 (de) Verwendung von "xylyloxy alkyl amines" für die Behandlung von Tinnitus
RU2005120779A (ru) Производные пиразола
DK0837680T3 (da) Anvendelse af phenoxy-pyridinderivater til behandling af sygdomme, som forårsages af forstyrrelser i dopaminsystemet
RU97107473A (ru) Бициклические производные амидина, которые можно использовать в терапии
RU2000119133A (ru) Новое применение местных анестетиков для лечения сосудистых головных болей

Legal Events

Date Code Title Description
A201 Request for examination
N231 Notification of change of applicant
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20050930

Year of fee payment: 8

LAPS Lapse due to unpaid annual fee